Prescribing overview
Sileo is an oromucosal gel for canine noise aversion, not an interchangeable injectable sedative.
Key prescribing checks
- The label excludes dogs with severe cardiovascular, respiratory, liver or kidney disease, shock and specified states of severe debilitation or environmental stress.
- Review sedation risk and concurrent central nervous system depressants. An already sedated patient requires reassessment rather than routine repeat administration.
- Train the handler in the supplied syringe’s locking mechanism and handling instructions. Accidental human exposure can be medically significant.
- Noise-related distress still warrants a broader behavioral assessment; the product does not identify the underlying cause of every fearful episode.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Dogs
FDA-approved veterinary labelNoise aversion
Safety below 16 weeks unestablished.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Reduces noradrenaline release through alpha-2 receptor agonism.
Absorption, distribution, metabolism and elimination
Canine oromucosal absorption avoids first-pass metabolism; swallowing can undermine effectiveness.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Sileo
U.S. canine oromucosal gel.
Contraindications · when not to use
- Severe cardiovascular, respiratory, liver or kidney disease; shock, severe debilitation or stress from extreme heat/cold/fatigue; hypersensitivity to dexmedetomidine or excipients.
Precautions & monitoring
- Label additionally says not to administer with pre-existing hypotension, hypoxia or bradycardia, or while sedated from earlier administration. Safety in breeding/pregnant/lactating dogs, dogs under 16 weeks or with relevant dental/gingival disease is unestablished. Prevent human exposure; pregnant handlers should avoid administration.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Sedation, vomiting and reduced heart rate can occur.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
| Species & indication | Labeled regimen | Eligibility & source |
|---|---|---|
| Dogs; label weight table 4.4–220.5 lbNoise aversionSileo gel, 0.1 mg/mL dexmedetomidine hydrochloride equivalent | 125 micrograms/m², using the labeled weight-based syringe dots (0.25 mL/dot) Between cheek and gum · Initially 30–60 minutes before noise or at first signs; repeat ≥2 hours apart if signs recur Maximum five doses per noise event | Use exact label weight table and Sileo syringe; >6 dots divide between both sides. Do not repeat while sedated. Safety <16 weeks unestablished. Verify full dosing label ↗ |
If swallowed, wait at least two hours before another dose.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Monitoring
Assess sedation and cardiovascular status before redosing.
Client counseling
Adult handlers wear impermeable gloves; pregnant handlers should avoid administration.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Original package at 20–25°C. Reviewed label conflicts on opened-syringe reuse (two versus four weeks); verify current package instructions with prescriber/manufacturer.
Brands, formulations & ingredient identity
Active ingredients
Dexmedetomidine
Other searchable names: dexmedetomidine hydrochloride · dexmedetomidine oromucosal gel
Sileo is absorbed through the oral mucosa; it is not an injectable sedative and is not intended to be swallowed.
The gel delivery device and formulation are essential identity details. Another dexmedetomidine product is not a Sileo synonym.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Sileo
- Formulation
- Oromucosal gel
- Label / product scope
- Dogs
Route-specific canine noise-aversion product.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →